Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US military awards MediVector $138M for a much-needed, broad-spectrum flu therapeutic

This article was originally published in Scrip

Executive Summary

The Boston-based drug development firm, MediVector, has won a $138.5 million contract under the US Department of Defense’s Joint Project Manager Transformational Medical Technologies (JPM-TMT) initiative to further develop a broad-spectrum therapeutic against multiple influenza viruses, the oral drug favipiravir (T-705). It has been called a novel antiviral.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts